We are thrilled to announce that NNE has been honoured as a Børsen Gazelle Company 2024.
This prestigious award recognises the fastest-growing companies in Denmark based on public financial statements and six criteria, including a minimum of 100% growth over four years, which is a feat achieved by less than 1% of Danish companies.
Having increased our revenue by 46% in only one financial year and achieved an operating profit margin of 12% in 2023, NNE is now pleased to accept the prestigious award in October 2024.
CEO of NNE, Jesper Kløve expresses his pride, stating:
“Being recognised as a Børsen Gazelle Company 2024 showcases our impressive growth over the past years. This recognition is not just about our financial performance; it reflects our strong, supportive culture and commitment to the work we do enabling pharmaceutical companies to bring products to patients.”
Our journey to this achievement has been driven by a combination of effective management, innovation, and our ability to attract and retain talented and passionate employees. These factors have been crucial in meeting the financial growth criteria set by Børsen.
CFO of NNE, Christoffer Hviid adds:
“Our growth, well above 100% over the last four years, is indeed impressive. Equally noteworthy is our success in managing the growth in a sustainable way. While executing the largest pharma projects in NNE history, we have built the necessary support setup, increased our investments in technology and infrastructure, onboarded thousands of new colleagues, delivered strong profit margins, and preserved our unique NNE culture.”
Thank you!
This recognition is a testament to our collective efforts and dedication. We would like to extend our sincere thanks to all colleagues across NNE – in Denmark, India, and the US – and to our stakeholders for their continued support. We look forward to continuing our growth journey in years to come.